- Previous Close
0.6545 - Open
0.7096 - Bid 0.4515 x 200
- Ask 0.7840 x 200
- Day's Range
0.6000 - 0.7100 - 52 Week Range
0.6000 - 3.4600 - Volume
52,079 - Avg. Volume
57,058 - Market Cap (intraday)
25.383M - Beta (5Y Monthly) -1.45
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.25
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody which is in Phase II clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.
www.rallybio.comRecent News: RLYB
View MorePerformance Overview: RLYB
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RLYB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RLYB
View MoreValuation Measures
Market Cap
27.24M
Enterprise Value
-38.12M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
44.81
Price/Book (mrq)
0.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.91%
Return on Equity (ttm)
-68.85%
Revenue (ttm)
636k
Net Income Avi to Common (ttm)
-57.77M
Diluted EPS (ttm)
-1.3300
Balance Sheet and Cash Flow
Total Cash (mrq)
65.51M
Total Debt/Equity (mrq)
0.25%
Levered Free Cash Flow (ttm)
-28.05M